MAPT and Alzheimer disease: NPSs and cognition were assessed annually in participants (DLB n = 222; Alzheimer's disease [AD] n = 125) from the European DLB (E‐DLB) Consortium, and plasma phosphorylated tau‐181 (p‐tau181) and p‐tau231 concentrations were measured at baseline.